Sanofi and Regeneron have announced that they will cut the price of their cholesterol drug Praluent for Express Scripts customers in exchange for greater patient access.
Praluent, which lowers bad LDL cholesterol and reduces the risk of heart attacks, has a list price of more than $14,000 a year but according to Express Scripts, the price will be moved down to approximately $4,500–$6,600.
Sales of Praluent have been low as insurers reject nearly 70 percent of prescriptions.
Praluent will become exclusive to the Express Scripts’ national formulary for the drug class known as PCSK9 inhibitors.
Read the Reuters report